These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19496717)

  • 1. Novel therapeutics for patients with non-muscle-invasive bladder cancer.
    Svatek RS; Kamat AM; Dinney CP
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):807-13. PubMed ID: 19496717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role and rationale of gene therapy and other novel therapies in the management of NMIBC.
    Lojo Rial C; Wilby D; Sooriakumaran P
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1777-82. PubMed ID: 19954289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer.
    Horvath A; Mostafid H
    BJU Int; 2009 Mar; 103(6):726-9. PubMed ID: 19007379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways.
    Wallerand H; Bernhard JC; Culine S; Ballanger P; Robert G; Reiter RE; Ferrière JM; Ravaud A
    Urol Oncol; 2011; 29(1):4-11. PubMed ID: 19914099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endpoints of clinical trials for muscle-invasive bladder cancer.
    Tannock IF
    Prog Clin Biol Res; 1990; 353():65-74. PubMed ID: 2217428
    [No Abstract]   [Full Text] [Related]  

  • 6. Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
    Small EJ; Halabi S; Kantoff P; D'Amico A; Stadler W; Kelley WK; Mohler J; Bajorin D; Vogelzang NJ
    Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3596s-600s. PubMed ID: 16740791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Portillo J; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Montesinos M; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA
    J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial intelligence and bladder cancer arrays.
    Wild PJ; Catto JW; Abbod MF; Linkens DA; Herr A; Pilarsky C; Wissmann C; Stoehr R; Denzinger S; Knuechel R; Hamdy FC; Hartmann A
    Verh Dtsch Ges Pathol; 2007; 91():308-19. PubMed ID: 18314629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.
    deVere White RW; Katz MH; Steinberg GD
    J Urol; 2009 May; 181(5):1994-7. PubMed ID: 19286209
    [No Abstract]   [Full Text] [Related]  

  • 10. [Photodynamic therapy of superficial cancer of the urinary bladder to prevent relapse].
    Rusakov IG; Sokolov VV; Bystrov AA
    Vopr Onkol; 2006; 52(6):675-9. PubMed ID: 17338248
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.
    Ather MH; Zaidi M
    Urol J; 2009; 6(3):189-93. PubMed ID: 19711273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer.
    Gazzaniga P; Gradilone A; de Berardinis E; Sciarra A; Cristini C; Naso G; di Silverio F; Frati L; Aglianò AM
    BJU Int; 2009 Jul; 104(2):184-8. PubMed ID: 19154503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Searching for novel therapeutics and targets: insights from clinical trials.
    Mitra AP; Cote RJ
    Urol Oncol; 2007; 25(4):341-3. PubMed ID: 17628305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
    Azuma H; Yamamoto K; Inamoto T; Ibuki N; Kotake Y; Sakamoto T; Kiyama S; Ubai T; Takahara K; Segawa N; Narumi Y; Katsuoka Y
    Am J Clin Oncol; 2009 Dec; 32(6):592-606. PubMed ID: 19593084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved?
    Lammers RJ; Sylvester RJ; Lee CT; Witjes JA
    Urol Clin North Am; 2013 May; 40(2):155-64. PubMed ID: 23540774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Urological cancer].
    Miyanaga N; Akaza H
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):193-8. PubMed ID: 19223735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of Apaziquone in the treatment of bladder cancer.
    Caramés Masana F; de Reijke TM
    Expert Opin Pharmacother; 2017 Nov; 18(16):1781-1788. PubMed ID: 29034722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to improve drug delivery in bladder cancer therapy.
    Wirth M; Plattner VE; Gabor F
    Expert Opin Drug Deliv; 2009 Jul; 6(7):727-44. PubMed ID: 19538035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer.
    Dindyal S; Nitkunan T; Bunce CJ
    Photodiagnosis Photodyn Ther; 2008 Jun; 5(2):153-8. PubMed ID: 19356647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line therapy in bladder cancer.
    Bachner M; De Santis M
    Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.